You are here:

peginterferon alfa-2a (Pegasys)

Advice

In the absence of a submission from the holder of the marketing authorisation

peginterferon alfa-2a (Pegasys ®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: peginterferon alfa-2a (Pegasys)
SMC Drug ID: 1312/18
Manufacturer: Roche
Indication: Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 February 2018

Back